Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups.
The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. Around $25.6 billion had been raised by 556 first-time funds in 2022.
Can’t stop reading? Read more
Chicago Atlantic expands into emerging markets private credit amid US investor pullback
Chicago Atlantic expands into emerging markets private credit amid US investor pullback Chicago...
Arcline-backed Arxis targets $11.2bn valuation in $1.06bn US IPO
Arcline-backed Arxis targets $11.2bn valuation in $1.06bn US IPO Arcline Investment Management is...
Triton Fund 6 signs deal to acquire Integris Composites from Agilitas
Triton Fund 6 signs deal to acquire Integris Composites from Agilitas Triton Fund 6 has agreed to...